179 related articles for article (PubMed ID: 36007681)
1. Research progress of bone-targeted drug delivery system on metastatic bone tumors.
Hu B; Zhang Y; Zhang G; Li Z; Jing Y; Yao J; Sun S
J Control Release; 2022 Oct; 350():377-388. PubMed ID: 36007681
[TBL] [Abstract][Full Text] [Related]
2. Design of Nanodrug Delivery Systems for Tumor Bone Metastasis.
Zhai X; Peng S; Zhai C; Wang S; Xie M; Guo S; Bai J
Curr Pharm Des; 2024; 30(15):1136-1148. PubMed ID: 38551047
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of Cancer Chemotherapeutic Efficacy via Bone-Targeted Drug Delivery Carrier in Bone Metastases.
Xue X; Yu J; Lu F; Jiang H; Wang X
Drug Des Devel Ther; 2021; 15():4455-4468. PubMed ID: 34737552
[TBL] [Abstract][Full Text] [Related]
4. Bone-Targeted Drug Delivery Systems and Strategies for Treatment of Bone Metastasis.
Katsumi H; Yamashita S; Morishita M; Yamamoto A
Chem Pharm Bull (Tokyo); 2020; 68(7):560-566. PubMed ID: 32611993
[TBL] [Abstract][Full Text] [Related]
5. Potential of targeted drug delivery system for the treatment of bone metastasis.
Vinay R; KusumDevi V
Drug Deliv; 2016; 23(1):21-9. PubMed ID: 24839990
[TBL] [Abstract][Full Text] [Related]
6. Engineering small-molecule and protein drugs for targeting bone tumors.
Wang Y; Wang C; Xia M; Tian Z; Zhou J; Berger JM; Zhang XH; Xiao H
Mol Ther; 2024 May; 32(5):1219-1237. PubMed ID: 38449313
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow endothelium-targeted therapeutics for metastatic breast cancer.
Mai J; Huang Y; Mu C; Zhang G; Xu R; Guo X; Xia X; Volk DE; Lokesh GL; Thiviyanathan V; Gorenstein DG; Liu X; Ferrari M; Shen H
J Control Release; 2014 Aug; 187():22-9. PubMed ID: 24818768
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate-functionalized micelles for targeted delivery of curcumin to metastatic bone cancer.
Kamble S; Varamini P; Müllner M; Pelras T; Rohanizadeh R
Pharm Dev Technol; 2020 Nov; 25(9):1118-1126. PubMed ID: 32686553
[TBL] [Abstract][Full Text] [Related]
9. Experiments and synthesis of bone-targeting epirubicin with the water-soluble macromolecular drug delivery systems of oxidized-dextran.
Yu L; Cai L; Hu H; Zhang Y
J Drug Target; 2014 May; 22(4):343-51. PubMed ID: 24405056
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapy.
Zhu J; Huo Q; Xu M; Yang F; Li Y; Shi H; Niu Y; Liu Y
Nanoscale; 2018 Oct; 10(38):18387-18397. PubMed ID: 30256367
[TBL] [Abstract][Full Text] [Related]
11. New Progress in Improving the Delivery Methods of Bisphosphonates in the Treatment of Bone Tumors.
Zhong Y; Li S
Drug Des Devel Ther; 2021; 15():4939-4959. PubMed ID: 34916778
[TBL] [Abstract][Full Text] [Related]
12. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
13. Targeting bone microenvironments for treatment and early detection of cancer bone metastatic niches.
Yang H; Yu Z; Ji S; Huo Q; Yan J; Gao Y; Niu Y; Xu M; Liu Y
J Control Release; 2022 Jan; 341():443-456. PubMed ID: 34748870
[TBL] [Abstract][Full Text] [Related]
14. Calcium-bisphosphonate Nanoparticle Platform as a Prolonged Nanodrug and Bone-Targeted Delivery System for Bone Diseases and Cancers.
Lin Y; Villacanas MG; Zou H; Liu H; Carcedo IG; Wu Y; Sun B; Wu X; Prasadam I; Monteiro MJ; Li L; Xu ZP; Gu W
ACS Appl Bio Mater; 2021 Mar; 4(3):2490-2501. PubMed ID: 35014367
[TBL] [Abstract][Full Text] [Related]
15. The optimized drug delivery systems of treating cancer bone metastatic osteolysis with nanomaterials.
Cheng X; Wei J; Ge Q; Xing D; Zhou X; Qian Y; Jiang G
Drug Deliv; 2021 Dec; 28(1):37-53. PubMed ID: 33336610
[TBL] [Abstract][Full Text] [Related]
16. Implications of bone metastases and the benefits of bone-targeted therapy.
Lipton A
Semin Oncol; 2010 Oct; 37 Suppl 2():S15-29. PubMed ID: 21111244
[TBL] [Abstract][Full Text] [Related]
17. Engineered nanomedicine for myeloma and bone microenvironment targeting.
Swami A; Reagan MR; Basto P; Mishima Y; Kamaly N; Glavey S; Zhang S; Moschetta M; Seevaratnam D; Zhang Y; Liu J; Memarzadeh M; Wu J; Manier S; Shi J; Bertrand N; Lu ZN; Nagano K; Baron R; Sacco A; Roccaro AM; Farokhzad OC; Ghobrial IM
Proc Natl Acad Sci U S A; 2014 Jul; 111(28):10287-92. PubMed ID: 24982170
[TBL] [Abstract][Full Text] [Related]
18. In Vivo Evaluation of Reduction-Responsive Alendronate-Hyaluronan-Curcumin Polymer-Drug Conjugates for Targeted Therapy of Bone Metastatic Breast Cancer.
Wang K; Guo C; Dong X; Yu Y; Wang B; Liu W; Chen D
Mol Pharm; 2018 Jul; 15(7):2764-2769. PubMed ID: 29792799
[TBL] [Abstract][Full Text] [Related]
19. Development of PEGylated aspartic acid-modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis.
Yamashita S; Katsumi H; Hibino N; Isobe Y; Yagi Y; Tanaka Y; Yamada S; Naito C; Yamamoto A
Biomaterials; 2018 Feb; 154():74-85. PubMed ID: 29120820
[TBL] [Abstract][Full Text] [Related]
20. Basic and clinical associations between bone and cancer.
He F; Matsumoto Y
Immunol Med; 2020 Sep; 43(3):103-106. PubMed ID: 32301686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
